U.S. markets closed

Mylan N.V. Aandelen aan toonder (6MY.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
13.46-0.15 (-1.12%)
At close: 10:00AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.62
Open13.48
Bid13.21 x 100000
Ask13.31 x 100000
Day's Range13.46 - 13.48
52 Week Range11.60 - 21.00
Volume0
Avg. Volume278
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Milan judge seizes 2.3 mln euros from Novartis in fraud probe

      A Milan judge has seized 2.3 million euros ($2.7 million) from pharmaceutical multinational Novartis as part of a fraud investigation, a document seen by Reuters shows. The money has been sequestered from the company's Italian unit Novartis Farma SpA, suspected of selling medicines to hospitals at inflated prices as part of a scheme to fraudulently obtain reimbursement funds from the regional government. Novartis said in a statement it rejected the "groundless" accusations of the Milan prosecutors and had behaved with full transparency.

    • Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4
      Zacks

      Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

      The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

    • Barrons.com

      How Pfizer Plans to Lead the Industry in Gene Therapies

      The drugmaker is eager to recast itself as a high-multiple growth stock. The expected growth will be fired up by 25 product launches, which Pfizer is explaining in two days of online talks.